Skip to main content

InvestorNewsBreaks – RYAH Group Inc. (CSE: RYAH) Names New Director, CEO

RYAH Group (CSE: RYAH), a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry, has announced that its board of directors has nominated Dr. David R. Richards, PhD, FIoD, FRSA, CPsych, as a new director and the company’s chief executive officer. Richards comes to the new positions with impressive experience, including serving in leadership roles at Nortel Networks’ GM Global Data; GM Global Supercarriers; GM UK Switching; and Global ThinkQuest Champion at Oracle’s Education Foundation. He has served as CEO of Ellis Jones Solicitors, executive director of business development and marketing at AECC University College, senior vice president and director of the Dorset Chamber of Industry and Commerce and board director of the West Hants Lawn and Tennis Club. An author, independent consultant and advisor, Richards cofounded the MIT Innovation Lab and is a lifetime member of the think tank, engaging with global innovation leaders at institutions such as NASA, UNDP, Nortel, 3M, Pitney Bowes and others in sharing best practices and key insights enabling substantially improved returns on investments in innovation initiatives. The nomination is subject to approval by the Canadian Securities Exchange. “I am extremely excited to be joining RYAH, which has a strong team, board and IP portfolio, poised to address many imminent and exciting challenges and opportunities in ways that will benefit humanity and make the world a better place, driving the company’s growth, value and success,” said RYAH Group newly appointed CEO David R. Richards in the press release.

To view the full press release, visit

About RYAH Group Inc.

RYAH is a big data and technology company enabling valuable AI-powered predictive analytics of the efficacy of plant-based medicines and other nutraceuticals administered through its range of innovative IoT-connected medical devices including inhalers, patches and pens. RYAH’s robust big data platform, the only one of its kind in this space, aggregates and analyzes HIPAA-compliant patient data, helping doctors and patients personalize treatments, control dosages, and better predict and monitor outcomes. The data and derived insights are also highly valuable for hospitals, clinicians, medical scientists, insurance providers, dispensaries, licensed growers, producers and pharmaceutical companies, and to monitor and manage formulation effects on patients based on dosages, strains, demographics, specific conditions and a range of other factors. Exciting new directions under CEO Dr. David Richards’ leadership include R&D in the realm of blockchain, NFTs and cryptocurrency that will pave the way toward successful commercialization of RYAH’s big-data assets. Through the above along with a relentless focus on innovation and track record of developing win-win collaborative partnerships within relevant industries, RYAH is continuously building a unique and highly valuable IP portfolio. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.